4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells.

      Proceedings of the National Academy of Sciences of the United States of America
      Benzamides, Breast Neoplasms, metabolism, physiopathology, Cell Hypoxia, physiology, Cell Line, Tumor, Chromatin Immunoprecipitation, Digoxin, pharmacology, Female, Humans, Hypoxia-Inducible Factor 1, antagonists & inhibitors, Immunoblotting, Immunohistochemistry, Luciferases, Lymphangiogenesis, drug effects, Lymphatic Metastasis, Piperazines, Proto-Oncogene Proteins c-sis, Pyrimidines, RNA, Small Interfering, Transcriptional Activation

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Lymphatic dissemination from the primary tumor is a major mechanism by which breast cancer cells access the systemic circulation, resulting in distant metastasis and mortality. Numerous studies link activation of hypoxia-inducible factor 1 (HIF-1) with tumor angiogenesis, metastasis, and patient mortality. However, the role of HIF-1 in lymphatic dissemination is poorly understood. In this study, we show that HIF-1 promotes lymphatic metastasis of breast cancer by direct transactivation of the gene encoding platelet-derived growth factor B (PDGF-B), which has proliferative and chemotactic effects on lymphatic endothelial cells. Lymphangiogenesis and lymphatic metastasis in mice bearing human breast cancer orthografts were blocked by administration of the HIF-1 inhibitor digoxin or the tyrosine kinase inhibitor imatinib. Immunohistochemical analysis of human breast cancer biopsies demonstrated colocalization of HIF-1α and PDGF-B, which were correlated with lymphatic vessel area and histological grade. Taken together, these data provide experimental support for breast cancer clinical trials targeting HIF-1 and PDGF-B.

          Related collections

          Author and article information

          Comments

          Comment on this article